AAAAAA

   
Results: 1-9 |
Results: 9
RANDOMIZED COMPARISON OF CASODEX(TM) (BICALUTAMIDE) 150 MG MONOTHERAPY VERSUS CASTRATION IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED PROSTATE-CANCER
Authors: TYRRELL CJ KAISARY AV IVERSEN P ANDERSON JB BAERT L TAMMELA T CHAMBERLAIN M WEBSTER A BLACKLEDGE G
Citation: Cj. Tyrrell et al., RANDOMIZED COMPARISON OF CASODEX(TM) (BICALUTAMIDE) 150 MG MONOTHERAPY VERSUS CASTRATION IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED PROSTATE-CANCER, European urology, 33(5), 1998, pp. 447-456
NEW DEVELOPMENTS IN CANCER-TREATMENT WITH THE NOVEL THYMIDYLATE SYNTHASE INHIBITOR RALTITREXED (TOMUDEX)
Authors: BLACKLEDGE G
Citation: G. Blackledge, NEW DEVELOPMENTS IN CANCER-TREATMENT WITH THE NOVEL THYMIDYLATE SYNTHASE INHIBITOR RALTITREXED (TOMUDEX), British Journal of Cancer, 77, 1998, pp. 29-37
BICALUTAMIDE - A NEW ANTIANDROGEN FOR USE IN COMBINATION WITH CASTRATION FOR PATIENTS WITH ADVANCED PROSTATE-CANCER
Authors: BLACKLEDGE G KOLVENBAG G NASH A
Citation: G. Blackledge et al., BICALUTAMIDE - A NEW ANTIANDROGEN FOR USE IN COMBINATION WITH CASTRATION FOR PATIENTS WITH ADVANCED PROSTATE-CANCER, Anti-cancer drugs, 7(1), 1996, pp. 27-34
THE BASIC SCIENCE OF BICALUTAMIDE AS A ONCE-DAILY ORAL ANTIANDROGEN -DISCUSSION
Authors: MALKOWICZ SB FURR B ANDRIOLE GL BLACKLEDGE G DENIS L BLOCK N MONTIE JE SCHELLHAMMER PF SCHMIDT J LAVINE R OESTERLING JE
Citation: Sb. Malkowicz et al., THE BASIC SCIENCE OF BICALUTAMIDE AS A ONCE-DAILY ORAL ANTIANDROGEN -DISCUSSION, Urology, 47(1A), 1996, pp. 29-32
CLINICAL-TRIALS OF BICALUTAMIDE AS MONOTHERAPY FOR PROSTATE-CANCER - DISCUSSION
Authors: ANDRIOLE GL DENIS L BLACKLEDGE G SCHMIDT J SAGALOWSKY A IVERSEN P SOLOWAY M FURR B BLOCK N BANERJEE T YOUNG J KOLVENBAG GCM OESTERLING JE NIEH PTC MONTIE JE SCHELLHAMMER PF BALES GT KLEIN EA BROSMAN S
Citation: Gl. Andriole et al., CLINICAL-TRIALS OF BICALUTAMIDE AS MONOTHERAPY FOR PROSTATE-CANCER - DISCUSSION, Urology, 47(1A), 1996, pp. 48-53
THE EXPECTED VALUE OF BICALUTAMIDE IN THE MANAGEMENT OF PROSTATIC DISEASE - DISCUSSION
Authors: OESTERLING JE MCLEOD DG RICHIE JP MALKOWICZ SB ANDRIOLE GL SEIDMON J KOLVENBAG GJCM BLACKLEDGE G SCHMIDT J KLEIN EA SOLOWAY M MONTIE JE GOMELLA L HAAS G SCHER H RAMSEY EW BROSMAN S LYNCH D WAJSMAN Z BABAIAN R ROMAS N BLOCK N
Citation: Je. Oesterling et al., THE EXPECTED VALUE OF BICALUTAMIDE IN THE MANAGEMENT OF PROSTATIC DISEASE - DISCUSSION, Urology, 47(1A), 1996, pp. 90-96
EFFICACY AND TOLERABILITY OF CASODEX IN PATIENTS WITH ADVANCED PROSTATE-CANCER
Authors: LUNGLMAYR G ALFTHAN O ALTWEIN JE BLACKLEDGE G BLACKLOCK NJ BONO A BOUFFIOUX C CHANNER K DEBRUYNE F DENIS L DISILVERIO F GRASSET D HAEFLINGER JM HARLAND S HEIJBROEK RP HOISAETER PA IVERSEN P JAEGER N KEUPPENS F KHOE GS KLARSKOV P KONTTURI M KUBER W KUMS JJM LARDENOYE JG LEDUC A LUNGLMAYR G MOEHRING K NEWLING D PAVONEMACALUSO M PERMI J RASMUSSEN F ROSSETTI SR SANDER S SARRAMON JP SMITH PH TVETER K TYRRELL CJ USAI E VALLANCIEN GMB VANCANGH PJ VARENHORST E WEISSBACH L WHELAN P WILLIAMS JL ZALCBERG J ZATTONI F DAWES PM
Citation: G. Lunglmayr et al., EFFICACY AND TOLERABILITY OF CASODEX IN PATIENTS WITH ADVANCED PROSTATE-CANCER, Anti-cancer drugs, 6(4), 1995, pp. 508-513
A RANDOMIZED COMPARISON OF MONOTHERAPY WITH CASODEX 50 MG DAILY AND CASTRATION IN THE TREATMENT OF METASTATIC PROSTATE CARCINOMA
Authors: KAISARY AV TYRRELL CJ BEACOCK C LUNGLMAYR G DEBRUYNE F ARKELL D BAXTERSMITH D BLACKLEDGE G DIJKMAN GA FARRAR D KARTHAUS HFM KHOE GS KIL PJM KUBER W MARBERGER M OSBORNE D PFLUEGER H PLASMAN J PULL H PUM H SCHEPERS J SCHORN A SOLE G STACKL W URLESBERGER H VILITS P WALLACE DMA DAWES PM
Citation: Av. Kaisary et al., A RANDOMIZED COMPARISON OF MONOTHERAPY WITH CASODEX 50 MG DAILY AND CASTRATION IN THE TREATMENT OF METASTATIC PROSTATE CARCINOMA, European urology, 28(3), 1995, pp. 215-222
CASODEX - MECHANISMS OF ACTION AND OPPORTUNITIES FOR USAGE
Authors: BLACKLEDGE G
Citation: G. Blackledge, CASODEX - MECHANISMS OF ACTION AND OPPORTUNITIES FOR USAGE, Cancer, 72(12), 1993, pp. 3830-3833
Risultati: 1-9 |